Skip to main content
Caplight Logo









Neurogene

Neurogene

Public
New York City, New YorkBiotechhttps://www.neurogene.com

Neurogene is now publicly traded

The data on this page reflects Neurogene's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

PIPE

Nov 4, 2024

Total Funding Raised

$478.5M

Company Overview

Neurogene is a biotechnology company focused on developing gene therapy solutions that leverage its EXACT gene regulation technology to transform complex neurological diseases into manageable conditions.

Sector

Biotech

AI Layer

Non-AI

Keywords

AAV-based gene therapy for rare neurological diseaseEXACT transgene regulation platformgene therapy for Rett syndromeone-time curative gene therapyin-house gene therapy manufacturingMECP2 gene therapygene therapy for CLN5 Batten diseaseclinical-stage gene therapy companyAAV9 gene therapypediatric neurodegenerative disorder treatmentbiotechnology intellectual property licensing

Neurogene Comparables

Compare Neurogene with similar companies based on industry and business-model similarity.

Neurogene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mahzi Therapeutics
71%
Neela Therapeutics
70%
Jaguar Gene Therapy
70%

Neurogene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
PIPENov 4, 2024
Private PlacementDec 19, 2023
Series BDec 16, 2020
Series AFeb 12, 2019

Key People

Founding team and executive leadership

Rachel McMinn

Founder & CEO, President & CEO

Founding Team

Christine Mikail

President (CBO COO) & CFO

Executive Team

Julie Choi Jordan

Chief Medical Officer

Executive Team

Stuart Cobb

Chief Scientific Officer

Executive Team

Neurogene Investors

Notable investors and investment history

Neurogene investors
InvestorRounds
EcoR1 CapitalPrivate Placement, PIPE, Series A, Series B
Redmile GroupSeries B, Private Placement, PIPE, Series A
Janus Henderson GroupSeries B, Private Placement
Avidity PartnersSeries B, Private Placement
Commodore CapitalPIPE
ArrowMark PartnersSeries B, Private Placement
Casdin CapitalSeries B, Private Placement, PIPE

Neurogene Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neurogene Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersNew York City, New York
Employee Range137
Year Founded2001
Last FundingNov 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?